Trial Profile
Phase II trial of NF-kappa-B decoy oligonucleotide for the treatment of skin diseases.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2014
Price :
$35
*
At a glance
- Drugs AMG 0101 (Primary)
- Indications Dermatitis; Psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Meyer Pharmaceuticals; Transcription Factor Therapeutics
- 05 Sep 2009 New trial record.